The synthesis of nano electronics, genomics and proteomics is ushering new protocols for the detection and treatment of cancer and other diseases. NBiomics [enn-bee-omics] is uniquely positioning itself to contribute towards this revolution.
Cancers are responsible for more than one-fourth of the deaths worldwide. Early detection of cancer results into better disease management, reliable prognosis and drastically improves survival rate of patients. The specific isolation of circulating tumor cells with nano-textured aptamer-functionalized microfluidic device falls into next generation cancer diagnostics market which was $776 million in 2010 and is expected to surpass $5 billion in 5 years.
Our goal is to produce a device that can detect the existence of cancer by enumerating circulating tumor cells way before emergence of clinical symptoms. This device can be relevant to in vitro/point-of-care (POC) diagnostic market. POC market was $13.7 billion in 2010 and is expected to grow at 8-9% in next 5 years. Our technique can identify a few CTCs in 1 ml sample of blood, which can be drawn during annual physical check-up. This is bound to capture major share of the next generation cancer diagnostics market.
Research conducted so far has identified processes that achieve the goal of identifying CTCs based on over expression of specific surface-based receptors. A number of publications and Intellectual Property has been produced.
Company Details
- Founded
- -
- Address
- Arlington, Arlington,texas,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://nbiomics.com
- HQ
- Arlington, Texas
Nbiomics Questions
Nbiomics's website is http://nbiomics.com
Nbiomics's LinkedIn profile is https://www.linkedin.com/company/nbiomics
Nbiomics's industry is
Biotechnology Research
Nbiomics's categories are Biotechnology Research
Nbiomics's founding year is 2012
